Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04143412
Other study ID # RAAS blockers in albuminuria
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 4, 2019
Est. completion date March 2020

Study information

Verified date January 2020
Source Beni-Suef University
Contact Mostafa O El Mokadem, M.D.
Phone +201009414408
Email mostafa.elmokadem9@med.bsu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of our work is to compare the antiproteinuric efficacy of ACEI monotherapy, Selective MRA monotherapy and their combination in mildly hypertensive patients with type 2 diabetes mellitus and microalbuminuria


Description:

Diabetic nephropathy (DN) is the most common cause renal failure in Western countries, responsible for 45% of patients on renal replacement therapy.Diabetic nephropathy was characterized in the early stage by increased albumin excretion in urine, known as microalbuminuria. (DN) results from interactions between different pathological factors that include hyperglycemia, increased activity of the renin-angiotensin-aldosterone-system (RAAS), uncontrolled high systemic and glomerular pressure . (DN) optimal therapy continues to evolve. The main lines of treatment include strict glycemic and blood pressure (BP) control. The angiotensin converting enzyme (ACE) inhibitors have been known to reduce proteinuria both in normotensive and hypertensive patients with diabetic nephropathy and in hypertensive individuals with end stage renal failure . The mechanism by which ACE inhibitors exert their effect on proteinuria reduction is still unknown. The control of high systemic arterial pressure can be beneficial by reducing the filtration pressure. However, no association has been found between antihypertensive effect and proteinuria reduction in several studies. Microalbuminuria which is an early sign of nephropathy can be decreased also by use of Angiotensin receptor blockers (ARBs) in patients with type 2 diabetes mellitus . Insufficient blockade of aldosterone may lead to inadequate anti-albuminuric effects. Studies show that renin-angiotensin-aldosterone system inhibition with ACEI/ARB alone sometimes does not achieve optimal renoprotective effects and does not reduce progression of renal disease, despite therapy. Addition of mineralocorticoid receptor antagonists (MRAs) to angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy was found to reduce proteinuria in patients diabetic nephropathy and can delay progression of renal dysfunction.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date March 2020
Est. primary completion date February 2020
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria:

- Adult male and non-pregnant female patients with established diagnosis of type 2 DM at least five years ago with glycosylated hemoglobin (HbA1c) = 8.5%

- Age 30-80 Y

- Stage 1 hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) and microalbuminuria diagnosed by measuring Urinary albumin/creatinine ratio (UACR) . Microalbuminuria was defined at a level between (30-300 mg/g)

- Patients included in our study had never been treated with ACEIs, ARBs or aldosterone antagonists, serum potassium level = 3.5 and = 5.0 mmol/L before randomization with estimated glomerular filtration rate (e GFR) =50 mL/min/1.73 m2

Exclusion Criteria:

- Patients with type 1 diabetes mellitus

- Patients with BP = 160/100 mmHg

- Patients with secondary hypertension

- Non-diabetic nephropathy including (chronic glomerulonephritis, polycystic kidney disease and nephrosclerosis),

- Confirmed bilateral renal artery stenosis or stenosis of the renal artery in solitary functioning kidney

- History of New York Heart Association functional class III and IV heart failure

- Patients with rapid progression of kidney disease and women who were pregnant, breast-feeding, or planning to become pregnant during the study period

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tritace (Ramipril 10 mg)
Stratified randomized clinical trial

Locations

Country Name City State
Egypt Faculty of Medicine,Beni-Suef University Bani Suwayf

Sponsors (1)

Lead Sponsor Collaborator
Beni-Suef University

Country where clinical trial is conducted

Egypt, 

References & Publications (8)

Cagnoni F, Njwe CA, Zaninelli A, Ricci AR, Daffra D, D'Ospina A, Preti P, Destro M. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination. Vasc Health Risk Manag. 2010 Aug 9;6:549-59. Review. — View Citation

Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy. J Diabetes Investig. 2011 Aug 2;2(4):243-7. doi: 10.1111/j.2040-1124.2011.00131.x. Review. — View Citation

Cooper LB, Lippmann SJ, Greiner MA, Sharma A, Kelly JP, Fonarow GC, Yancy CW, Heidenreich PA, Hernandez AF. Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. J Am Heart Assoc. 2017 Dec 23;6(12). pii: e006540. doi: 10.1161/JAHA.117.006540. — View Citation

Espinel E, Agraz I, Ibernon M, Ramos N, Fort J, Serón D. Renal Biopsy in Type 2 Diabetic Patients. J Clin Med. 2015 May 18;4(5):998-1009. doi: 10.3390/jcm4050998. Review. — View Citation

Galle J. Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med. 2008 Jul;5 Suppl 1:S36-43. doi: 10.1038/ncpcardio0806. Review. — View Citation

Jalal S, Sofi FA, Abass SM, Alai MS, Bhat MA, Rather HA, Lone NA, Siddiqi MA. Effect of amlodipine and lisinopril on microalbuminuria in patients with essential hypertension: A prospective study. Indian J Nephrol. 2010 Jan;20(1):15-20. doi: 10.4103/0971-4065.62090. — View Citation

Satirapoj B, Adler SG. Prevalence and Management of Diabetic Nephropathy in Western Countries. Kidney Dis (Basel). 2015 May;1(1):61-70. doi: 10.1159/000382028. Epub 2015 May 1. Review. — View Citation

Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. Diabetic nephropathy. Diabetol Metab Syndr. 2009 Sep 21;1(1):10. doi: 10.1186/1758-5996-1-10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary albumin/creatinin ratio (UACR) Percentage change in albumin/creatinin ratio compared with the baseline value 24 weeks
Secondary Blood pressure change in blood pressure level 24 weeks
Secondary estimated Glomerular Filtration Rate (e GFR) change in estimated Glomerular Filtration Rate (e GFR) 24 weeks
Secondary Serum K change in serum K level 24 weeks
See also
  Status Clinical Trial Phase
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT04549324 - Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Recruiting NCT03502031 - Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy Phase 4
Completed NCT03681704 - the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD Phase 1
Completed NCT03681249 - the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD Early Phase 1
Withdrawn NCT03504566 - Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) Phase 4
Completed NCT03889236 - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. N/A
Completed NCT06326034 - Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients Phase 4
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Not yet recruiting NCT05373004 - Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease Phase 2/Phase 3
Recruiting NCT03622762 - Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT03445247 - Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy N/A
Not yet recruiting NCT06068439 - Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy Phase 2/Phase 3
Not yet recruiting NCT06222476 - Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. N/A
Completed NCT05487755 - Investigational and Comparative Study in the Management of Diabetic Nephropathy Phase 3
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2
Recruiting NCT05888909 - Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Not yet recruiting NCT04962399 - Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
Not yet recruiting NCT03591939 - T-regulatory Cells in Diabetic Type Two Nephropathy
Active, not recruiting NCT03859817 - Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient